Related references
Note: Only part of the references are listed.A let-7 microRNA-binding site polymorphism in 3 '-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy
W. Zhang et al.
ANNALS OF ONCOLOGY (2011)
Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours
S. Weidlich et al.
BRITISH JOURNAL OF CANCER (2011)
MicroRNA dysregulation in colorectal cancer: a clinical perspective
Y. Dong et al.
BRITISH JOURNAL OF CANCER (2011)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Restitution of Tumor Suppressor MicroRNAs Using a Systemic Nanovector Inhibits Pancreatic Cancer Growth in Mice
Dipankar Pramanik et al.
MOLECULAR CANCER THERAPEUTICS (2011)
miR-143 Overexpression Impairs Growth of Human Colon Carcinoma Xenografts in Mice with Induction of Apoptosis and Inhibition of Proliferation
Pedro M. Borralho et al.
PLOS ONE (2011)
MicroRNA expression profiling to identify and validate reference genes for relative quantification in colorectal cancer
Kah Hoong Chang et al.
BMC CANCER (2010)
A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors
Andrey Loboda et al.
BMC MEDICAL GENOMICS (2010)
Relevance of miR-21 and miR-143 expression in tissue samples of colorectal carcinoma and its liver metastases
Vlastimil Kulda et al.
CANCER GENETICS AND CYTOGENETICS (2010)
Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
Marc Peeters et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
Alberto Bardelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
Jean-Yves Douillard et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
MicroRNAs and Their Therapeutic Potential for Human Diseases: MicroRNAs, miR-143 and -145, Function as Anti-oncomirs and the Application of Chemically Modified miR-143 as an Anti-cancer Drug
Yukio Kitade et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2010)
Regulation of Heparin-Binding EGF-Like Growth Factor by miR-212 and Acquired Cetuximab-Resistance in Head and Neck Squamous Cell Carcinoma
Hiromitsu Hatakeyama et al.
PLOS ONE (2010)
Genetic modulation of the Let-7 microRNA binding to KRAS 3′-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan
F. Graziano et al.
PHARMACOGENOMICS JOURNAL (2010)
MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer
E. K. O. Ng et al.
BRITISH JOURNAL OF CANCER (2009)
Clinicopathological significance of microRNA-31,-143 and-145 expression in colorectal cancer
Chao-Jie Wang et al.
DISEASE MARKERS (2009)
MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells
Pedro M. Borralho et al.
FEBS JOURNAL (2009)
Evaluation of High-Resolution Melting Analysis as a Diagnostic Tool to Detect the BRAF V600E Mutation in Colorectal Tumors
Martin Pichler et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2009)
Role of miR-143 targeting KRAS in colorectal tumorigenesis
X. Chen et al.
ONCOGENE (2009)
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
Astrid Lievre et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Analyzing real-time PCR data by the comparative C-T method
Thomas D. Schmittgen et al.
NATURE PROTOCOLS (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer
O. Slaby et al.
ONCOLOGY (2007)
MicroRNA signatures in human cancers
George A. Calin et al.
NATURE REVIEWS CANCER (2006)
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment
A Grothey et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Metastatic renal carcinoma comprehensive prognostic system
J Atzpodien et al.
BRITISH JOURNAL OF CANCER (2003)
Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria
V Trillet-Lenoir et al.
BRITISH JOURNAL OF RADIOLOGY (2002)
Share Paper
